Skip to main content

4 Result(s)

within Philip Galebach Remove this filter

and

  1. Article

    Open Access

    Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States

    Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutili...

    Eytan M. Stein, Min Yang, Annie Guerin, Wei Gao… in Health and Quality of Life Outcomes (2018)

    Download PDF (622 KB) View Article

  2. No Access

    Article

    Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients

    Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of second-...

    Edmond Bendaly, Anand A. Dalal, Kenneth Culver, Philip Galebach… in Advances in Therapy (2017)

  3. No Access

    Article

    Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study

    This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received c...

    Edmond Bendaly, Anand A. Dalal, Kenneth Culver, Philip Galebach… in Advances in Therapy (2017)

  4. No Access

    Article

    Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review

    Patients with multiple sclerosis (MS) experience varying rates of brain volume (BV) loss ranging from 0.5 to 1.5 % per year. In addition, 66 % of patients with MS experience cognitive impairment, resulting in ...

    Timothy Vollmer, Lynn Huynh, Caroline Kelley, Philip Galebach… in Neurological Sciences (2016)